Zydus Lifesciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5% (USRLD: EMLA® Cream, 2.5%/2.5%).

Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia.

Lidocaine and Prilocaine cream will be produced at the Group's topical manufacturing site at Changodar, Ahmedabad.

Lidocaine and Prilocaine cream had annual sales of USD 22.05 mn in the United States (IQVIA MAT October 2024). The group now has 412 approvals and has so far filed over 473* ANDAs since the commencement of the filing process in FY 2003-04.

Powered by Capital Market - Live News

Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia. Lidocaine and Prilocaine cream will be produced at the Group’s topical manufacturing site at Changodar, Ahmedabad.

Lidocaine and Prilocaine cream had annual sales of $22.05 million in the United States (IQVIA MAT October 2024).

The group now has 412 approvals and has so far filed over 473 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company’s consolidated net profit increased 13.8% to Rs 911.20 crore in Q2 FY25 as against Rs 800.70 crore posted in Q2 FY24. Revenue from operations jumped 20.1% to Rs 5,113.60 crore in the quarter ended 30 September 2024.

The scrip rose 0.52% to Rs 984.20 on the BSE.

Powered by Capital Market - Live News

Zydus Lifesciences announced that Zydus Animal Health and Investments, a wholly owned subsidiary (ZAHL) had acquired 65,06,500 equity shares of Re. 1 each fully paid-up, representing 6.5% of the total paid-up share capital (Sale Shares) of Mylab Discovery Solutions (Mylab) from Rising Sun Holding (RHSPL) at an agreed consideration of Rs. 106 crore vide a Share Purchase Agreement (SPA) executed by ZAHL, RHSPL and Mylab on 23 June 2023.

Now, pursuant to the terms and conditions of the SPA, ZAHL has exercised its Put Option right to sell the Sale Shares back to RHSPL and RHSPL has agreed to acquire the Sale Shares at the original consideration amount i.e. Rs. 106 crore.

The Board of Directors of ZAHL at their meeting held today i.e. 16 December 2024, approved the disinvestment of Sale Shares, as per the terms and conditions of the SPA. Post that, ZAHL, RSHPL and Mylab have executed the termination deed.

Powered by Capital Market - Live News

Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 984.6, up 1.03% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Zydus Lifesciences Ltd has dropped around 1.98% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has dropped around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 6.68 lakh shares today, compared to the daily average of 11.59 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 986.9, up 0.7% on the day. Zydus Lifesciences Ltd is up 55.45% in last one year as compared to a 18.09% gain in NIFTY and a 38.64% gain in the Nifty Pharma index.

The PE of the stock is 22.53 based on TTM earnings ending September 24.

Powered by Capital Market - Live News